PolyNovo Limited
PolyNovo Limited
- P/E ratio
- 79.25
Your view on PNV.AX
Overview
What the company does, where it operates, and who runs it.
About PolyNovo Limited
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Bruce Peatey
- Headquarters
- 320 Lorimer Street, Port Melbourne, VIC, AU
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Bruce Peatey
- Headquarters
- 320 Lorimer Street, Port Melbourne, VIC, AU
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong.
The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn.
It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products.
The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for PolyNovo Limited from FRC's valuation model, read against the market price. PNV.AX last traded at AUD 0.88, 79.2× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for PolyNovo Limited. Starting points for PolyNovo Limited: P/E 79.2, EPS AUD 0.01, beta 1.35 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for PolyNovo Limited. PolyNovo Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for PolyNovo Limited. Trailing twelve-month EPS for PolyNovo Limited stands at AUD 0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Earnings Estimate
| EPS | Current QtrJun 2017 | Next QtrJun 2018 | Current YearFY Jun 2027 | Next YearFY Jun 2028 |
|---|---|---|---|---|
| Avg. estimate | −AUD 0.01 | −AUD 0.01 | AUD 0.01 | AUD 0.02 |
| Low estimate | −AUD 0.01 | −AUD 0.01 | AUD 0.01 | AUD 0.02 |
| High estimate | −AUD 0.01 | −AUD 0.01 | AUD 0.01 | AUD 0.03 |
| No. of analysts | 2 | 2 | 4 | 4 |
| Year-ago EPS | — | — | AUD 0.011 | — |
| Growth | — | — | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrJun 2017 | Next QtrJun 2018 | Current YearFY Jun 2027 | Next YearFY Jun 2028 |
|---|---|---|---|---|
| Avg. estimate | AUD 6.09M | AUD 7.41M | AUD 161.78M | AUD 185.70M |
| Low estimate | AUD 5.82M | AUD 7.08M | AUD 159.70M | AUD 181.80M |
| High estimate | AUD 6.12M | AUD 7.45M | AUD 164.00M | AUD 189.50M |
| No. of analysts | 2 | 2 | 7 | 7 |
| Year-ago revenue | — | — | AUD 143.71M | — |
| Growth | — | — | +12.6% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 20, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for PolyNovo Limited. PolyNovo Limited has reported as a listed company since 1998. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| ARX.AXAroa Biosurgery Limited | Healthcare | Medical - Devices | — | ||
| CMB.AXCambium Bio Limited | Healthcare | Biotechnology | — | ||
| OCC.AXOrthocell Limited | Healthcare | Biotechnology | — | ||
| OSX.AXOsteopore Limited | Healthcare | Medical - Instruments & Supplies | — | ||
| TRP.AXTissue Repair Ltd | Healthcare | Biotechnology | — | ||
| TTX.AXTetratherix Ltd. | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| ARMMArmm Inc. | Healthcare | OTC | $106,246 | ||
| ASAPFAurora Spine Corporation | Healthcare | OTC | $16.4M | ||
| ASG.VAurora Spine Corporation | Healthcare | TSXV | $16.2M | ||
| ASTI.CNAquarius Surgical Technologies Inc. | Healthcare | CNQ | — | ||
| AT1.AXAtomo Diagnostics Limited | Healthcare | ASX | — | ||
| ATECAlphatec Holdings, Inc. | Healthcare | NASDAQ | $1.1B | ||
| AVH.AXAVITA Medical, Inc. | Healthcare | ASX | — | ||
| AVHHLAVITA Medical, Inc. | Healthcare | OTC | $99.4M | ||
| AVRAnteris Technologies Global Corp. | Healthcare | NASDAQ | $507.9M | ||
| AVR.AXAnteris Technologies Ltd | Healthcare | ASX | — | ||
| AXGNAxoGen, Inc. | Healthcare | NASDAQ | $3.4B | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VXUSVanguard Total International Stock ETF | $163.2B in assets | 0.00% | |
| VEAVanguard FTSE Developed Markets ETF | $231.6B in assets | 0.00% | |
| VSSVanguard FTSE All-World ex-US Small-Cap ETF | $11.6B in assets | 0.01% | |
| SPDWState Street SPDR Portfolio Developed World ex-US ETF | $41.0B in assets | 0.00% | |
| AVDSAvantis International Small Cap Equity ETF | $379M in assets | 0.01% | |
| DFISDimensional - International Small Cap ETF | $5.8B in assets | 0.00% | |
| VIU.TOVanguard FTSE Developed All Cap ex North America Index ETF | $11.4B in assets | 0.00% | |
| VSGXVanguard ESG International Stock ETF | $6.7B in assets | 0.00% | |
Largest holders first, then the funds most concentrated in PNV.AX.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for PolyNovo Limited. Coverage tracks PolyNovo Limited within Medical - Devices (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of PolyNovo Limited.